Zobrazeno 1 - 10
of 29
pro vyhledávání: ''
Autor:
Chris Twelves, Matthew Guo, Larisa Reyderman, Ishtiaq Husain Zubairi, R. Morrison, Nicola Cresti, Claudio Savulsky, Alan Anthoney, Vladimir Semiglazov, Ruth Plummer, T.R. Jeffry Evans, Constanta Timcheva
Publikováno v:
British Journal of Cancer
Background: \ud Capecitabine and eribulin are widely used as single agents in metastatic breast cancer (MBC) and have nonoverlapping toxicities.\ud \ud Methods: \ud In phase 1b (dose escalation), patients with advanced, treatment-refractory, solid tu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::97bccd2276eddef510b3a7b2fcc67aa0
https://eprints.whiterose.ac.uk/148290/1/s41416-018-0366-5.pdf
https://eprints.whiterose.ac.uk/148290/1/s41416-018-0366-5.pdf
Publikováno v:
European Journal of Drug Metabolism and Pharmacokinetics
Background and Objectives Previous pharmacokinetic studies of the inhaled corticosteroid, fluticasone furoate (FF), and the long-acting, beta2-receptor agonist, vilanterol (VI) have been performed in relatively small populations using non-compartment
Autor:
Ian C. Reid, Justin H. G. Williams, Chamandeep K. Thind, Anthony Ormerod, Shantini A. Rice, Peter McCaffery
Publikováno v:
Psychopharmacology
Rationale The acne drug isotretinoin has 13-cis retinoic acid as its active agent. Adverse effects that have been described include severe depression. Animal studies indicate that the hippocampus is particularly sensitive to retinoic acid. Changes in
Autor:
Tamotsu Sagawa, Kan Yonemori, Kenji Tamura, Makoto Kodaira, Fumihiko Hirai, Toshio Kawata, Ben Hatano, Yuki Yokoi, Koshi Fujikawa, Yasuo Takahashi, Tsuyoshi Shirakawa, Taito Esaki
Publikováno v:
Cancer Chemotherapy and Pharmacology
Purpose This was the first Phase I study to assess the safety and tolerability of the tablet formulation of olaparib (Lynparza™), an oral poly(ADP-ribose) polymerase inhibitor, in Japanese patients with advanced solid tumours. The pharmacokinetic p
Autor:
Hiroshi Nokihara, Tomohide Tamura, Hao Xiong, Vincent L. Giranda, Hideyuki Hashiba, Stacie Peacock Shepherd, Jane Qian, Shigehiro Yagishita, Shintaro Kanda, Satoru Kitazono, Yutaka Fujiwara, Hidehito Horinouchi, Hidenori Mizugaki, Noboru Yamamoto
Publikováno v:
Cancer Chemotherapy and Pharmacology
Abstact Introduction Veliparib is a potent, orally bioavailable PARP inhibitor that enhances efficacy of DNA-damaging chemotherapeutic agents. The study objectives were to determine the recommended phase 2 dose (RPTD) of veliparib plus carboplatin an
Publikováno v:
Journal of Gastroenterology
Background Vaniprevir (MK-7009) is a hepatitis C virus (HCV) non-structural 3/4a protease inhibitor which significantly increases virologic response rates in HCV genotype (GT) 1-infected patients when added to peginterferon and ribavirin (PR). Method
Autor:
Sebastián Videla, Jesús Cebrecos, Mounia Lahjou, France Wagner, Pascal Guibord, Zhengguo Xu, Anna Cabot, Mercedes Encabo, Gregorio Encina, Eric Sicard, Artur Sans
Publikováno v:
Drugs in R&D
Background Doxylamine succinate, an ethanolamine-based antihistamine, is used in the short-term management of insomnia because of its sedative effects. No data on the dose proportionality of the pharmacokinetics of doxylamine are available, although
Publikováno v:
European Journal of Nutrition
Background Lactic fermentation of foods increases the availability of iron as shown in a number of studies throughout the years. Several explanations have been provided such as decreased content of inhibitory phytate, increased solubility of iron, an
Publikováno v:
Clinical Drug Investigation
Background CER-001 comprises recombinant human apolipoprotein A-I complexed with phospholipids that mimics natural, nascent, pre-β high-density lipoprotein (HDL). We present animal model data showing dose-dependent increases in cholesterol efflux wi
Publikováno v:
Investigational New Drugs
Eribulin mesylate (Halaven™, E7389) is a synthetic analog of the marine natural product halichondrin B that acts via a mechanism distinct from conventional tubulin-targeted agents. This Phase I study (clinicaltrials.gov identifier: NCT00326950) was